CompletedPhase 1NCT06283589
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
Studying Calciphylaxis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inozyme Pharma
- Principal Investigator
- Kurt Gunter, MDInozyme Pharma
- Intervention
- INZ-701(drug)
- Enrollment
- 11 enrolled
- Eligibility
- 18-69 years · All sexes
- Timeline
- 2024 – 2024
Study locations (2)
- South Florida Nephrology Research, Coral Springs, Florida, United States
- Elixia Health, Hollywood, Florida, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06283589 on ClinicalTrials.govOther trials for Calciphylaxis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07511283Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)Odense University Hospital
- RECRUITINGNANCT04654000Rheopheresis as Adjuvant Treatment of CalciphylaxisUniversity Hospital, Lille
- RECRUITINGPHASE3NCT05018221Better Evidence and Translation for CalciphylaxisUniversity of Sydney
- RECRUITINGEARLY PHASE1NCT04592640Human Amniotic-Derived Mesenchymal Stem Cell Therapy for CalciphylaxisThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT03032835Partners Calciphylaxis BiobankMassachusetts General Hospital
- RECRUITINGNCT02280733A Real-World Registry of Chronic Wounds and UlcersU.S. Wound Registry